The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
10X Genomics Inc's Score
Industry at a Glance
Industry Ranking
21 / 208
Overall Ranking
77 / 4593
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
19
analysts
Buy
Current Rating
16.333
Target Price
-0.77%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
10X Genomics Inc Highlights
StrengthsRisks
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 18.28% year-on-year.
Undervalued
The company’s latest PE is -29.41, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 117.21M shares, decreasing 17.35% quarter-over-quarter.
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.
Ticker SymbolTXG
Company10X Genomics Inc
CEOMr. Serge Wilson Saxonov, Ph.D.
Websitehttps://www.10xgenomics.com/
FAQs
What is the current price of 10X Genomics Inc (TXG)?
The current price of 10X Genomics Inc (TXG) is 18.340.
What is the symbol of 10X Genomics Inc?
The ticker symbol of 10X Genomics Inc is TXG.
What is the 52-week high of 10X Genomics Inc?
The 52-week high of 10X Genomics Inc is 17.700.
What is the 52-week low of 10X Genomics Inc?
The 52-week low of 10X Genomics Inc is 6.780.
What is the market capitalization of 10X Genomics Inc?
The market capitalization of 10X Genomics Inc is 2.32B.
What is the net income of 10X Genomics Inc?
The net income of 10X Genomics Inc is -182.63M.
Is 10X Genomics Inc (TXG) currently rated as Buy, Hold, or Sell?
According to analysts, 10X Genomics Inc (TXG) has an overall rating of Buy, with a price target of 16.333.
What is the Earnings Per Share (EPS TTM) of 10X Genomics Inc (TXG)?
The Earnings Per Share (EPS TTM) of 10X Genomics Inc (TXG) is -0.624.